The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

Peer C Tfelt-Hansen; Jes Olesen

doi:10.1007/s10194-012-0428-7

The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

Peer C Tfelt-Hansen, Jes Olesen

Department of Neurology

37 Citations (Scopus)

Abstract

Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P

Original language	English
Journal	Journal of Headache and Pain
Volume	13
Issue number	4
Pages (from-to)	271-5
Number of pages	5
ISSN	1129-2369
DOIs	https://doi.org/10.1007/s10194-012-0428-7
Publication status	Published - 2012

Access to Document

10.1007/s10194-012-0428-7

Cite this

@article{db4f637f3f3043a8b2a7579d403e6e5b,

title = "The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials",

abstract = "Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P ",

author = "Tfelt-Hansen, \{Peer C\} and Jes Olesen",

year = "2012",

doi = "10.1007/s10194-012-0428-7",

language = "English",

volume = "13",

pages = "271--5",

journal = "Journal of Headache and Pain",

issn = "1129-2369",

publisher = "BioMed Central",

number = "4",

}

TY - JOUR

T1 - The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks

T2 - a review of two placebo-controlled phase II trials

AU - Tfelt-Hansen, Peer C

AU - Olesen, Jes

PY - 2012

Y1 - 2012

N2 - Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P

AB - Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P

UR - https://www.scopus.com/pages/publications/84861480975

U2 - 10.1007/s10194-012-0428-7

DO - 10.1007/s10194-012-0428-7

M3 - Review

C2 - 22430431

SN - 1129-2369

VL - 13

SP - 271

EP - 275

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

IS - 4

ER -

The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

Abstract

Access to Document

Other files and links

Fingerprint

Cite this